Jeffrey Trigilio is the founder of Cullinan Oncology. Cullinan Oncology has raised $231M in total funding. Latest round: Series C. Based in Cambridge, USA.
Jeffrey Trigilio is the Chief Financial Officer of Obsidian Therapeutics, a clinical-stage biotechnology company developing engineered cell and gene therapies. He previously held the CFO position at Cullinan Oncology, where he guided its initial public offering and helped secure business development transactions. Prior to that, he was CFO at Amylyx Pharmaceuticals and VP of Corporate Finance at BlueRock Therapeutics, which was acquired by Bayer AG.
Full founder directory · Investor directory · Company funding database · Fundraising library